Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 151

1.

Mammalian target of rapamycin (mTOR) activation in focal cortical dysplasia and related focal cortical malformations.

Wong M.

Exp Neurol. 2013 Jun;244:22-6. doi: 10.1016/j.expneurol.2011.10.002. Epub 2011 Oct 8. Review.

2.

mTOR-dependent abnormalities in autophagy characterize human malformations of cortical development: evidence from focal cortical dysplasia and tuberous sclerosis.

Yasin SA, Ali AM, Tata M, Picker SR, Anderson GW, Latimer-Bowman E, Nicholson SL, Harkness W, Cross JH, Paine SM, Jacques TS.

Acta Neuropathol. 2013 Aug;126(2):207-18. doi: 10.1007/s00401-013-1135-4. Epub 2013 Jun 2.

PMID:
23728790
3.

Cell injury and premature neurodegeneration in focal malformations of cortical development.

Iyer A, Prabowo A, Anink J, Spliet WG, van Rijen PC, Aronica E.

Brain Pathol. 2014 Jan;24(1):1-17. doi: 10.1111/bpa.12060. Epub 2013 May 7.

PMID:
23586324
4.

Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: From tuberous sclerosis to common acquired epilepsies.

Wong M.

Epilepsia. 2010 Jan;51(1):27-36. doi: 10.1111/j.1528-1167.2009.02341.x. Epub 2009 Oct 8. Review.

5.

Focal malformations of cortical development: new vistas for molecular pathogenesis.

Lim KC, Crino PB.

Neuroscience. 2013 Nov 12;252:262-76. doi: 10.1016/j.neuroscience.2013.07.037. Epub 2013 Jul 25. Review.

PMID:
23892008
6.

mTOR signaling in epilepsy: insights from malformations of cortical development.

Crino PB.

Cold Spring Harb Perspect Med. 2015 Apr 1;5(4). pii: a022442. doi: 10.1101/cshperspect.a022442. Review.

7.

Expression of tuberin and hamartin in tuberous sclerosis complex-associated and sporadic cortical dysplasia of Taylor's balloon cell type.

Grajkowska W, Kotulska K, Matyja E, Larysz-Brysz M, Mandera M, Roszkowski M, Domańska-Pakieła D, Lewik-Kowalik J, Jóźwiak S.

Folia Neuropathol. 2008;46(1):43-8.

8.
9.

Altered inhibition in tuberous sclerosis and type IIb cortical dysplasia.

Talos DM, Sun H, Kosaras B, Joseph A, Folkerth RD, Poduri A, Madsen JR, Black PM, Jensen FE.

Ann Neurol. 2012 Apr;71(4):539-51. doi: 10.1002/ana.22696. Epub 2012 Mar 23.

10.

Focal brain malformations: seizures, signaling, sequencing.

Crino PB.

Epilepsia. 2009 Oct;50 Suppl 9:3-8. doi: 10.1111/j.1528-1167.2009.02289.x.

11.

Mammalian target of rapamycin (mTOR) pathways in neurological diseases.

Wong M.

Biomed J. 2013 Mar-Apr;36(2):40-50. doi: 10.4103/2319-4170.110365. Review.

12.

Subependymal giant cell astrocytoma: a lesion with activated mTOR pathway and constant expression of glutamine synthetase.

Buccoliero AM, Caporalini C, Giordano F, Mussa F, Scagnet M, Moscardi S, Baroni G, Genitori L, Taddei GL.

Clin Neuropathol. 2016 Sep-Oct;35(5):295-301. doi: 10.5414/NP300936.

PMID:
27390104
13.

mTOR pathway inhibition as a new therapeutic strategy in epilepsy and epileptogenesis.

Citraro R, Leo A, Constanti A, Russo E, De Sarro G.

Pharmacol Res. 2016 May;107:333-43. doi: 10.1016/j.phrs.2016.03.039. Epub 2016 Apr 2. Review.

PMID:
27049136
14.

Expression patterns of synaptic vesicle protein 2A in focal cortical dysplasia and TSC-cortical tubers.

Toering ST, Boer K, de Groot M, Troost D, Heimans JJ, Spliet WG, van Rijen PC, Jansen FE, Gorter JA, Reijneveld JC, Aronica E.

Epilepsia. 2009 Jun;50(6):1409-18. doi: 10.1111/j.1528-1167.2008.01955.x. Epub 2009 Feb 12.

15.

[Activation of mTOR in maldeveloped balloon cells and dysmorphic neurons of type II focal cortical dysplasia].

Lin K, Lin YX, Kang DZ, Ye ZX, Wang XF.

Zhonghua Bing Li Xue Za Zhi. 2013 May;42(5):311-5. doi: 10.3760/cma.j.issn.0529-5807.2013.05.005. Chinese.

PMID:
24004587
16.

mTOR and Epileptogenesis in Developmental Brain Malformations.

Wong M, Crino PB.

In: Noebels JL, Avoli M, Rogawski MA, Olsen RW, Delgado-Escueta AV, editors. Jasper's Basic Mechanisms of the Epilepsies [Internet]. 4th edition. Bethesda (MD): National Center for Biotechnology Information (US); 2012.

17.

Expression of TRPV1 in cortical lesions from patients with tuberous sclerosis complex and focal cortical dysplasia type IIb.

Shu HF, Yu SX, Zhang CQ, Liu SY, Wu KF, Zang ZL, Yang H, Zhou SW, Yin Q.

Brain Dev. 2013 Mar;35(3):252-60. doi: 10.1016/j.braindev.2012.04.007. Epub 2012 May 28.

PMID:
22647236
18.

[Expression of PI3K pathway proteins in refractory epilepsy associated with cortical malformation development].

Ni HC, Sun FH, Piao YS, Ma XL, Lu DH.

Zhonghua Bing Li Xue Za Zhi. 2012 Jun;41(6):391-5. doi: 10.3760/cma.j.issn.0529-5807.2012.06.007. Chinese.

PMID:
22932407
19.

Activation of extracellular regulated kinase and mechanistic target of rapamycin pathway in focal cortical dysplasia.

Patil VV, Guzman M, Carter AN, Rathore G, Yoshor D, Curry D, Wilfong A, Agadi S, Swann JW, Adesina AM, Bhattacharjee MB, Anderson AE.

Neuropathology. 2016 Apr;36(2):146-56. doi: 10.1111/neup.12242. Epub 2015 Sep 18.

20.

Downregulation of CD47 and CD200 in patients with focal cortical dysplasia type IIb and tuberous sclerosis complex.

Sun FJ, Zhang CQ, Chen X, Wei YJ, Li S, Liu SY, Zang ZL, He JJ, Guo W, Yang H.

J Neuroinflammation. 2016 Apr 19;13(1):85. doi: 10.1186/s12974-016-0546-2.

Supplemental Content

Support Center